IOL Chemicals and Pharmaceuticals Limited – Investor Presentation Summary

Key Operational Highlights

  • Total installed capacity of 2,13,126 MTPA comprising 30,726 MTPA API and 1,82,400 MTPA Specialty Chemicals
  • Among largest global manufacturers of Iso Butyl Benzene (IBB) worldwide with 12,000 MTPA capacity
  • Ethyl Acetate manufacturing capacity of over 1,20,000 MTPA
  • Acetic Anhydride manufacturing capacity of 32,000 MTPA for captive and merchant sale
  • Asia's first continuous dual technology plant for MCA and Acetyl Chloride using green chemistry
  • Non-Ibuprofen API contribution to pharmaceutical revenue rose to 45% in Q2 FY27

Key drivers of operational performance: Portfolio diversification across multiple therapeutic areas, backward integration across key products, and expansion of high-value APIs.

Segment-wise Performance

Performance shown through consolidated financials without specific segment breakdown. The company operates in Pharmaceuticals (APIs) and Specialty Chemicals segments.

Explanation of significant changes in segment performance: Growth driven by diversified API portfolio expansion and strong demand in specialty chemicals across multiple end-user industries including pharmaceuticals, food processing, paints, textiles, agro chemicals, polymers, and personal care.

Financial Highlights

Revenue: Rs. 795.0 Cr (Q2 FY27), Rs. 1,551.3 Cr (H1 FY27)

EBITDA: Rs. 114.9 Cr (Q2 FY27), Rs. 226.6 Cr (H1 FY27)

PAT: Rs. 65.0 Cr (Q2 FY27), Rs. 129.5 Cr (H1 FY27)

EPS: Rs. 2.21 (Q2 FY27), Rs. 4.41 (H1 FY27)

Margins: EBITDA Margin 14.4% (Q2 FY27), 14.5% (H1 FY27); PAT Margin 8.1% (Q2 FY27), 8.3% (H1 FY27)

YoY comparison: Q2 FY27 Revenue up 40.1% YoY, PAT up 116.8% YoY; H1 FY27 Revenue up 38.6% YoY, PAT up 102.5% YoY

QoQ comparison: Q2 FY27 Revenue up 5.1% QoQ, PAT up 0.9% QoQ

Drivers of financial performance: Higher revenue growth, operational efficiencies, and portfolio diversification toward high-margin products.

Comparison to market estimates: Not specified

Key Risks: Not explicitly disclosed in presentation

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not specified with exact figures

Exports Contribution Guidance: 25%-30% targeted for FY27

Regional Breakdown: Company has regulatory approvals for multiple international markets including USFDA, EUGMP, EDQM, MFDS Korea, ANVISA Brazil, CDE China, Russian Federation, and others enabling global expansion.

Balance Sheet Snapshot

Net Debt/Equity: Not explicitly calculated but borrowings of ₹194.2 Cr (current) against equity of ₹1,925.5 Cr

Reserves: Other equity of ₹1,866.8 Cr

Current Assets/Liabilities: Current assets ₹1,366.0 Cr vs current liabilities ₹801.3 Cr

Working Capital/Leverage Metrics: Trade receivables ₹689.2 Cr, Inventories ₹464.4 Cr, Trade payables ₹487.8 Cr

Financial Health Insights: Strong equity base, manageable debt levels, and improved profitability supporting financial health.

Capex & Cash Flow Health

Capital Expenditure: ₹200-250 Cr guidance for FY26-27; Specific projects include ₹110 Cr formulations facility, ₹35 Cr specialty chemical facility, ₹350 Cr Ibuprofen capacity expansion

Free Cash Flow: Not explicitly stated

Operating Cash Flow: Net cash from operating activities ₹8.3 Cr for H1 FY27

Net Debt Movement: Not explicitly disclosed

Investment Rationale: Focus on capacity expansion, forward integration into formulations, and technology upgrades to capture higher value in pharmaceutical value chain.

Strategic & R&D Initiatives

Investments in Innovation: 120-member R&D team including 50+ scientists; DSIR approved facility; Working on generic molecules with latest equipment

Expected impact on growth: Formulations facility (1,500 million tablets annually) to serve European customers and deepen relationships; Ibuprofen capacity expansion to 18,000 MTPA to meet growing demand

Strategic Rationale: Building scale, deepening customer partnerships, moving up the value chain through formulations and CDMO, and expanding specialty chemicals range.

Industry Trends & Business Environment

Macro/Industry Trends: China+1 supply chain shift benefiting Indian API manufacturers; Shift towards high-value APIs; Patent cliff creating opportunities for generic APIs; Rising chronic disease demand; Government PLI schemes supporting API self-reliance

Impact on Company: Positioned to benefit from global supply chain diversification; Expanding high-value API portfolio; Increasing regulated market exports with 14 USFDA DMFs and 22 EDQM CEPs

Management Commentary & Growth Outlook

Strategic Outlook: Focused on serving existing European customers, broadening offerings beyond APIs, and deepening long-term relationships

FY Guidance: EBITDA Margin 14%-15%; Exports Contribution 25%-30%; Capex ₹200-250 Crs

Market Share Targets: Not explicitly stated

Risks and Opportunities: Not explicitly highlighted beyond industry trends

ESG Updates

  • ECOVADIS Gold Medal recipient ranking among top 5% of companies assessed globally for ESG performance
  • Water neutral status maintained
  • ₹4.65 Cr total CSR investment during FY26 impacting ~5.5 lakh lives
  • ₹2.79 crore invested in healthcare initiatives including hospital upgrades and medical supplies
  • ₹1.40 crore invested in social upliftment initiatives including plantation drives and pond restoration
  • ₹47 lakh invested in education initiatives including smart classrooms and school renovations

Certifications & Accreditations

  • USFDA Approved Facility • EUGMP Certification • EDQM Certificate of Suitability • DMF Registration From MFDS Korea • ANVISA, Brazil • CDE of NMPA, China • GMP Certificate by Russian Federation • Kosher Certified • WHOGMP Certified • REACH Certificate • Halal Certified • Multiple ISO certifications (9001:2015, 14001:2015, 45001:2018, 27001, 37001) • Social Accountability SA 8000